Elizabeth D Kantor1, Christina C Newton2, Edward L Giovannucci3,4, Marjorie L McCullough2, Peter T Campbell2, Eric J Jacobs2. 1. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA. kantore@mskcc.org. 2. Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA. 3. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 4. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
PURPOSE: Use of glucosamine supplements has been associated with reduced risk of colorectal cancer (CRC) in previous studies; however, information on this association remains limited. METHODS: We examined the association between glucosamine use and CRC risk among 113,067 men and women in the Cancer Prevention Study II Nutrition Cohort. Glucosamine use was first reported in 2001 and updated every 2 years thereafter. Participants were followed from 2001 through June of 2011, during which time 1440 cases of CRC occurred. RESULTS: As has been observed in prior studies, current use of glucosamine, modeled using a time-varying exposure, was associated with lower risk of CRC (HR 0.83; 95% CI 0.71-0.97) compared to never use. However, for reasons that are unclear, this reduction in risk was observed for shorter-duration use (HR 0.68; 95% CI 0.52-0.87 for current users with ≤ 2 years use) rather than longer-duration use (HR 0.90; 95% CI 0.72-1.13 for current users with 3 to < 6 years of use; HR 0.99; 95% CI 0.76-1.29 for current users with ≥ 6 years of use). CONCLUSIONS: Further research is needed to better understand the association between glucosamine use and risk of CRC, and how this association may vary by duration of use.
PURPOSE: Use of glucosamine supplements has been associated with reduced risk of colorectal cancer (CRC) in previous studies; however, information on this association remains limited. METHODS: We examined the association between glucosamine use and CRC risk among 113,067 men and women in the Cancer Prevention Study II Nutrition Cohort. Glucosamine use was first reported in 2001 and updated every 2 years thereafter. Participants were followed from 2001 through June of 2011, during which time 1440 cases of CRC occurred. RESULTS: As has been observed in prior studies, current use of glucosamine, modeled using a time-varying exposure, was associated with lower risk of CRC (HR 0.83; 95% CI 0.71-0.97) compared to never use. However, for reasons that are unclear, this reduction in risk was observed for shorter-duration use (HR 0.68; 95% CI 0.52-0.87 for current users with ≤ 2 years use) rather than longer-duration use (HR 0.90; 95% CI 0.72-1.13 for current users with 3 to < 6 years of use; HR 0.99; 95% CI 0.76-1.29 for current users with ≥ 6 years of use). CONCLUSIONS: Further research is needed to better understand the association between glucosamine use and risk of CRC, and how this association may vary by duration of use.
Authors: Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci Journal: Int J Cancer Date: 2016-07-18 Impact factor: 7.396
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Daniel O Clegg; Domenic J Reda; Crystal L Harris; Marguerite A Klein; James R O'Dell; Michele M Hooper; John D Bradley; Clifton O Bingham; Michael H Weisman; Christopher G Jackson; Nancy E Lane; John J Cush; Larry W Moreland; H Ralph Schumacher; Chester V Oddis; Frederick Wolfe; Jerry A Molitor; David E Yocum; Thomas J Schnitzer; Daniel E Furst; Allen D Sawitzke; Helen Shi; Kenneth D Brandt; Roland W Moskowitz; H James Williams Journal: N Engl J Med Date: 2006-02-23 Impact factor: 91.245
Authors: Elizabeth D Kantor; Johanna W Lampe; Sandi L Navarro; Xiaoling Song; Ginger L Milne; Emily White Journal: J Altern Complement Med Date: 2014-04-16 Impact factor: 2.579
Authors: Elizabeth D Kantor; Kelli O'Connell; Peter S Liang; Sandi L Navarro; Edward L Giovannucci; Mengmeng Du Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-03-01 Impact factor: 4.090
Authors: Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci Journal: J Altern Complement Med Date: 2020-12-07 Impact factor: 2.579
Authors: Jessica M Moon; Peter Finnegan; Richard A Stecker; Hanna Lee; Kayla M Ratliff; Ralf Jäger; Martin Purpura; Carolyn M Slupsky; Maria L Marco; Craig J Wissent; Jason Theodosakis; Chad M Kerksick Journal: Nutrients Date: 2021-06-24 Impact factor: 5.717